Efficacy and Durability of Nevirapine in Antiretroviral-Experienced Patients
- 1 September 2003
- journal article
- review article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 34, S53-S58
- https://doi.org/10.1097/00126334-200309011-00008
Abstract
The non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) has been used as a component of salvage therapy for patients who have experienced virologic failure while taking nucleosides and protease inhibitors (PIs). In spite of broad cross-resistance within the NNRTI class, NVP may also play a role in salvage therapy for patients who have experienced failure while taking NNRTIs. Another role for NVP in treatment-experienced patients is in so-called "PI switch" strategies, in which NVP is substituted for a PI within a virologically successful combination regimen. This paper reviews the clinical data that support the use of NVP in salvage regimens and PI switch strategies.Keywords
This publication has 10 references indexed in Scilit:
- A compromise strategy for patients with multiple drug failureAIDS, 2001
- Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency Virus–Infected, Amprenavir‐Experienced Subjects: AIDS Clinical Trials Group Protocol 373The Journal of Infectious Diseases, 2001
- Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patientAIDS, 2001
- Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimensAIDS, 2001
- Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNAClinical Infectious Diseases, 2000
- Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapyAIDS, 2000
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapineAIDS, 1999
- Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1999
- A Pilot Study of Nevirapine, Indinavir, and Lamivudine among Patients with Advanced Human Immunodeficiency Virus Disease Who Have Had Failure of Combination Nucleoside TherapyThe Journal of Infectious Diseases, 1998